BioXcel Therapeutics (BTAI) Liabilities and Shareholders Equity (2017 - 2026)

BioXcel Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $34.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 11.77% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at $149.5 million (down 21.81% YoY), while the FY2025 annual figure was $44.9 million, up 17.16% from the prior year.
• Liabilities and Shareholders Equity was $34.0 million for Q1 2026 at BioXcel Therapeutics, down from $44.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $248.2 million in Q2 2022 to a low of $25.8 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $107.5 million across 5 years, with a median of $73.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 64.2% in 2023, then grew 17.16% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $205.9 million in 2022, then tumbled by 64.2% to $73.7 million in 2023, then tumbled by 47.98% to $38.3 million in 2024, then advanced by 17.16% to $44.9 million in 2025, then slipped by 24.25% to $34.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $34.0 million (Q1 2026), $44.9 million (Q4 2025), and $44.8 million (Q3 2025), per Business Quant data.